Loading clinical trials...

Clinical Applications of Advanced Ophthalmic Imaging | Clinical Trials | Clareo Health

RECRUITINGNA

Clinical Applications of Advanced Ophthalmic Imaging

NCT03135327•University of Miami

Summary

The purpose of this study is to determine the clinical application of advanced ophthalmic imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI), slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls. There are two phases in this study. The first phase is an observational phase which studies the eye in various conditions. The second phase is an interventional phase which studies the changes in the eyes after taking an over-the-counter medical food (Ocufolin) for 6 months.

Eligibility

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Observational Phase 1 Group
•1. Self-reported normal healthy subjects;
•2. Clinical diagnosis of Alzheimer's Disease, mild cognitive impairment, multiple sclerosis, dry eye, myopia, diabetics and stroke;
•3. Who can keep the eye open for imaging.
•The participant will be eligible for entry in the study if s/he:
•1. Is at least 18 years old and has full legal capacity to volunteer;
•2. Has read and signed the IRB Informed Consent Document;
•3. Is willing and able to follow participant instructions;
•4. Has clear corneas and crystalline lens;
•5. Initial visual acuities were 20/80 or better;
+5 more criteria

Exclusion Criteria

•1. who can not read and sign the ICF;
•2. who can not receiving ophthalmic imaging;
•3. who cannot tolerate bright light during imaging.
•Interventional Phase 2 Group:
•The subjects will be ineligible for entry into the study if s/he:
•1. Has an active ocular disease;
•2. Has had surgery or an eye injury within 6 months.

Locations (1)

Bascom Palmer Eye Institute

Miami, Florida, United States

Key Dates

Start Date

January 1, 2007

Primary Completion Date

December 31, 2029

Completion Date

December 31, 2029

Last Updated

August 12, 2025

Enrollment

5,000

ESTIMATED participants

Conditions

Multiple SclerosisDry Eye SyndromesDiabetic RetinopathyPresbyopiaMyopiaDementia

Interventions

Ocufolin

DIETARY_SUPPLEMENT

Contacts

Jianhua Wang, MD, PhD

CONTACT

3054825010 jwang3@med.miami.edu

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634

Multiple SclerosisMultiple Sclerosis-Relapsing-Remitting+1 more

View study

RECRUITINGPHASE3

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504

Secondary Progressive Multiple Sclerosis (SPMS)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 12, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Clinical Applications of Advanced Ophthalmic Imaging

Inclusion Criteria

Exclusion Criteria

Intermittent Hypoxia in Persons With Multiple Sclerosis

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study